Quantum BioPharma Ltd. (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to support the Phase 2 clinical trial of Lucid-MS, its investigational drug candidate for progressive multiple sclerosis (MS). The agreement follows U.S. Food and Drug Administration clearance of its Investigational New Drug application in August 2026 and moves the program toward clinical implementation with a contract research organization experienced in central nervous system and MS studies.
The deal matters because it pairs Quantum's novel approach with a CRO that has deep expertise in MS trials, potentially accelerating the path to clinical data. Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. This mechanism could offer a complementary or alternative strategy for progressive forms of MS, which currently have limited treatment options.
The randomized, double-blind, placebo-controlled trial will evaluate the candidate's safety, tolerability and efficacy using clinical and radiological measures. Although preclinical research and Phase 1 testing have provided encouraging findings, Lucid-MS remains investigational, and the company has not yet announced enrollment dates or trial sites. Investors can view the full article at https://ibn.fm/0IAIS and find more information about Quantum BioPharma at www.QuantumBioPharma.com. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
The announcement also highlights the role of specialized communications in reaching investors. The press release was distributed by InvestorWire, a platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets and social media distribution to millions of followers. Such broad reach can help emerging biotech companies like Quantum BioPharma gain visibility among investors and the public as they advance clinical programs.
For Quantum BioPharma, the agreement with Thermo Fisher represents a tangible step toward executing its Phase 2 plan, but key details such as trial sites and enrollment timelines remain undisclosed. The company's ability to initiate and complete the trial will be closely watched, given the unmet need in progressive MS and the differentiated mechanism of Lucid-MS. If successful, the program could position Quantum as a contender in the MS space, though significant clinical and regulatory hurdles remain.
